AstraZeneca Plc on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when ...

A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide ...

But is the higher incidence of grade 3/4 adverse events "a worthwhile price to pay?" exper ...

AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new ...

Oral drug shows responses across 6 tumor types in patients resistant to immunotherapy, with durable benefits and manageable safety in a ...

Significant reductions seen in non-small cell lung cancer, breast cancer, colorectal cancer, and hepatocellular carcinoma.

Obesity has been associated with multiple gastrointestinal cancers, but patients with these malignancies and obesity who have ...

Readouts in hepatocellular carcinoma, as well as pancreatic, gastric and salivary gland cancer, are capturing attention at ...

PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing ...

SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rationally designed molecular glue ...

Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are ...